Search Results - "Atadja, P"

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies by DeAngelo, D J, Spencer, A, Bhalla, K N, Prince, H M, Fischer, T, Kindler, T, Giles, F J, Scott, J W, Parker, K, Liu, A, Woo, M, Atadja, P, Mishra, K K, Ottmann, O G

“…Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces…”
Get full text

SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells by Scuto, A, Kirschbaum, M, Buettner, R, Kujawski, M, Cermak, J M, Atadja, P, Jove, R

“…We explored the activity of SIRT1 activators (SRT501 and SRT2183) alone and in combination with panobinostat in a panel of malignant lymphoid cell lines in…”
Get full text

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair by Maiso, P, Colado, E, Ocio, E M, Garayoa, M, Martín, J, Atadja, P, Pandiella, A, San-Miguel, J F

“…Acute myeloid leukemia (AML) is a clonal disorder characterized by the accumulation of myeloid blasts in the bone marrow. Here, we report the effects of the…”
Get full text

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic VkMYC multiple myeloma by Matthews, G M, Lefebure, M, Doyle, M A, Shortt, J, Ellul, J, Chesi, M, Banks, K-M, Vidacs, E, Faulkner, D, Atadja, P, Bergsagel, P L, Johnstone, R W

“…Multiple myeloma (MM) is an incurable malignancy with an unmet need for innovative treatment options. Histone deacetylase inhibitors (HDACi) are a new class of…”
Get full text

Increased Activity of p53 in Senescing Fibroblasts by Atadja, Peter, Wong, Howard, Garkavtsev, Igor, Veillette, Claude, Riabowol, Karl

“…The p53 tumor-suppressor protein binds DNA and activates the expression of a 21-kDa protein that inhibits both the activity of cyclin-dependent kinases and the…”
Get full text

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo by Weisberg, E, Catley, L, Kujawa, J, Atadja, P, Remiszewski, S, Fuerst, P, Cavazza, C, Anderson, K, Griffin, J D

“…NVP-LAQ824 is a novel potent hydroxamic acid-derived histone deacetylase inhibitor that induces apoptosis in nanomolar concentrations in myeloid leukemia cell…”
Get full text

7054 POSTER Concurrent Histone Deacetylase and Mammalian Target of Rapamycin Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated With Alterations in MicroRNA Expression by Ellis, L, Lehet, K, Ramakrishnan, S, Miles, K.M, Wang, D, Liu, S, Atadja, P, Carducci, M.A, Pili, R

Get full text

PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance by Atadja, P, Watanabe, T, Xu, H, Cohen, D

“…The expression of drug efflux mechanisms by cancer cells during chemotherapy leads to multidrug resistance (MDR) and constitutes a major obstacle in the…”
Get full text

161 POSTER Potent anticancer activity of panobinostat (LBH589) in models of hormone-refractory prostate cancer (HRPC): targeting the androgen receptor by Shao, W, Growney, J, O'Connor, G, Feng, Y, Scher, H, Yao, Y.M, Fawell, S, Atadja, P

Get full text

151 POSTER Efficacy of panobinostat (LBH589) in lung cancer: potent anticancer activity in both in vitro and in vivo tumor models by Atadja, P, Shao, W, Wang, Y, Growney, J, Feng, Y, Yao, Y.M, Wallace, A, Crisanti, C, Fawell, S, Albelda, S

Get full text

Loss of serum response element-binding activity and hyperphosphorylation of serum response factor during cellular aging by Atadja, P W, Stringer, K F, Riabowol, K T

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors by Bali, Purva, Pranpat, Michael, Bradner, James, Balasis, Maria, Fiskus, Warren, Guo, Fei, Rocha, Kathy, Kumaraswamy, Sandhya, Boyapalle, Sandhya, Atadja, Peter, Seto, Edward, Bhalla, Kapil

“…The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce acetylation and inhibit the ATP…”
Get full text

702 POSTER Phase I pharmacokinetic and pharmacodynamic study of once-weekly IV LBH589 by Sharma, S, Vogelzang, N.J, Beck, J, Patnaik, A, Mita, M, Dugan, M, Hwang, A, Culver, K, Atadja, P, Prince, H.M

Get full text

701 POSTER Phase I study of oral LBH589 in advanced solid tumours and non-Hodgkin's lymphoma by Prince, H.M, George, D, Patnick, A, Mita, M, Atadja, P, Dugan, M, Butterfoss, D, Culver, K, Burris, H.S, Beck, J

Get full text

Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein by Watanabe, T, Uchiyama, N, Roninson, I B, Cohen, D, Atadja, P

“…P-glycoprotein (P-gp) is a transmembrane glycoprotein that confers multidrug resistance (MDR). It has been demonstrated that the Gly185 residue within the…”
Get more information

Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family by Gao, Lin, Cueto, Maria A., Asselbergs, Fred, Atadja, Peter

“…We have cloned and characterized a human cDNA that belongs to the histone deacetylase family, which we designate as HDAC11. The predicted HDAC11 amino acid…”
Get full text

Differential effects of transforming growth factor-beta 1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts by Edwards, D R, Leco, K J, Beaudry, P P, Atadja, P W, Veillette, C, Riabowol, K T

“…The balance between the activities of matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) is an important control point in…”
Get full text

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3 by George, Prince, Bali, Purva, Annavarapu, Srinivas, Scuto, Anna, Fiskus, Warren, Guo, Fei, Sigua, Celia, Sondarva, Gautam, Moscinski, Lynn, Atadja, Peter, Bhalla, Kapil

“…Present studies show that LBH589, a novel cinnamic hydroxamic acid analog histone deacetylase inhibitor, induces acetylation of histone H3 and H4 and of heat…”
Get full text

Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 by QIAN, David Z, KATO, Yukihiko, SHABBEER, Shabana, WEI, Yongfeng, VERHEUL, Hendrik M. W, SALUMBIDES, Brenda, SANNI, Tolib, ATADJA, Peter, PILI, Roberto

“…Purpose: Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone deacetylase (HDAC) inhibitors…”
Get full text

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma by Ocio, Enrique M, Vilanova, David, Atadja, Peter, Maiso, Patricia, Crusoe, Edvan, Fernández-Lázaro, Diego, Garayoa, Mercedes, San-Segundo, Laura, Hernández-Iglesias, Teresa, de Alava, Enrique, Shao, Wenlin, Yao, Yung-Mae, Pandiella, Atanasio, San-Miguel, Jesús F

“…Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma. However, most…”
Get full text